Dengue vaccine tetravalent - Sanofi Pasteur

Drug Profile

Dengue vaccine tetravalent - Sanofi Pasteur

Alternative Names: ChimeriVax Tetravalent Dengue Vaccine; ChimeriVax-DEN1-4; ChimeriVax-Dengue; CYD dengue vaccine; CYD dengue vaccine - Sanofi; CYD-4444; CYD-5553; CYD-5555; CYD-TDV; Dengue fever vaccine - Sanofi; Dengue vaccine recombinant tetravalent - Sanofi; Dengue vaccine tetravalent - Sanofi; Dengue virus vaccine - Sanofi; Dengvaxia; Live, attenuated, dengue serotype 1, 2, 3, 4 virus vaccine; Tetravalent CYD 1,2,3,4 dengue; Tetravalent dengue vaccine - Sanofi; TV-CYD

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acambis; Sanofi Pasteur
  • Developer Sanofi Pasteur
  • Class Attenuated vaccines; Dengue vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Dengue

Most Recent Events

  • 01 Nov 2018 Planned Prescription Drug User Fee Act (PDUFA) date for Dengue (Prevention) in USA (SC) is 2019-05-01
  • 30 Oct 2018 Dengue vaccine receives priority review status for Dengue (Prevention) in USA (SC)
  • 30 Oct 2018 The US FDA accepts BLA for dengue vaccine for Dengue (Prevention) for review (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top